Paradigm partners with City St George’s to probe osteoarthritis bone lesions

Paradigm Biopharmaceuticals ( (AU:PAR) ) has issued an announcement.

Paradigm Biopharmaceuticals has entered a 12‑month research collaboration with City St George’s, University of London, a major UK centre for musculoskeletal and pain research, to study bone marrow lesions in osteoarthritis. The project will use advanced MRI alongside gene and protein profiling of tissue from knee replacement surgeries to clarify how pentosan polysulfate sodium affects bone, cartilage, and synovial inflammation.

The work aims to deepen understanding of PPS’ mechanism of action, especially its impact on bone marrow lesions that are increasingly linked to osteoarthritis pain and progression. Paradigm expects that evidence of PPS activity across multiple joint tissues could strengthen its positioning as a potential disease‑modifying therapy, differentiate it from current standard treatments, and support future pricing, reimbursement, and partnering discussions if results are positive.

The most recent analyst rating on (AU:PAR) stock is a Hold with a A$0.25 price target. To see the full list of analyst forecasts on Paradigm Biopharmaceuticals stock, see the AU:PAR Stock Forecast page.

More about Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals Ltd. is a late-stage drug development company focused on discovering, developing, and delivering pharmaceutical therapies to address unmet medical needs. Its current focus is on developing injectable pentosan polysulfate sodium for diseases driven by inflammation, particularly osteoarthritis, where it is conducting Phase 3 clinical trials.

Average Trading Volume: 949,768

Technical Sentiment Signal: Sell

Current Market Cap: A$115.7M

See more data about PAR stock on TipRanks’ Stock Analysis page.